(Adds Bristol Myers' defenses against some claims, paragraph 10) * Appeals court revives $6.7 billion case dismissed in 2024 * Bristol Myers accused of slow-walking drug approvals to avoid big payout
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)